Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $33.00

by · The Cerbat Gem

Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) had its target price lifted by Truist Financial from $30.00 to $33.00 in a research report sent to investors on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Several other research firms also recently issued reports on CNTA. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. B. Riley lifted their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Stephens started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Check Out Our Latest Report on Centessa Pharmaceuticals

Centessa Pharmaceuticals Stock Up 1.7%

CNTA opened at $22.42 on Thursday. Centessa Pharmaceuticals has a twelve month low of $9.60 and a twelve month high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The company’s 50-day moving average price is $26.04 and its two-hundred day moving average price is $21.39. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of -12.25 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, equities analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. This represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider directly owned 178,801 shares in the company, valued at approximately $5,364,030. The trade was a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 64,000 shares of company stock worth $1,674,460. 7.09% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its stake in Centessa Pharmaceuticals by 1,017.7% during the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock valued at $6,593,000 after purchasing an additional 240,039 shares during the last quarter. Tudor Investment Corp ET AL lifted its holdings in shares of Centessa Pharmaceuticals by 13.7% during the third quarter. Tudor Investment Corp ET AL now owns 57,810 shares of the company’s stock valued at $1,402,000 after purchasing an additional 6,959 shares in the last quarter. TCG Crossover Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 8.5% during the third quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after purchasing an additional 245,664 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at $2,772,000. Finally, Jain Global LLC bought a new stake in Centessa Pharmaceuticals in the 3rd quarter worth about $5,868,000. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

Recommended Stories